MA32283B1 - Composes cycliques condenses et utilisation de ceux-ci - Google Patents

Composes cycliques condenses et utilisation de ceux-ci

Info

Publication number
MA32283B1
MA32283B1 MA33304A MA33304A MA32283B1 MA 32283 B1 MA32283 B1 MA 32283B1 MA 33304 A MA33304 A MA 33304A MA 33304 A MA33304 A MA 33304A MA 32283 B1 MA32283 B1 MA 32283B1
Authority
MA
Morocco
Prior art keywords
cyclic compounds
condensed cyclic
relates
present
glucokinase activator
Prior art date
Application number
MA33304A
Other languages
Arabic (ar)
English (en)
Inventor
Tsuneo Yasuma
Nobuyuki Takakura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32283B1 publication Critical patent/MA32283B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne un activateur de glucokinase utile en tant qu'agent pharmaceutique tel qu'un agent pour la prophylaxie ou le traitement du diabète, de l'obésité et similaire. La présente invention concerne un activateur de glucokinase contenant un composé représenté par la formule (i) : dans laquelle chaque symbole est défini dans la spécification, ou un sel de celui-ci ou un promédicament de celui-ci.
MA33304A 2008-04-10 2010-11-01 Composes cycliques condenses et utilisation de ceux-ci MA32283B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008102691 2008-04-10
PCT/JP2009/057625 WO2009125873A1 (fr) 2008-04-10 2009-04-09 Composés cycliques condensés et utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
MA32283B1 true MA32283B1 (fr) 2011-05-02

Family

ID=40671202

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33304A MA32283B1 (fr) 2008-04-10 2010-11-01 Composes cycliques condenses et utilisation de ceux-ci

Country Status (34)

Country Link
US (1) US8673942B2 (fr)
EP (1) EP2276760B1 (fr)
JP (1) JP5528348B2 (fr)
KR (1) KR20110002472A (fr)
CN (1) CN102056924B (fr)
AR (1) AR073609A1 (fr)
AU (1) AU2009234666B2 (fr)
BR (1) BRPI0910912A2 (fr)
CA (1) CA2720686A1 (fr)
CO (1) CO6321240A2 (fr)
CR (1) CR11730A (fr)
CY (1) CY1115247T1 (fr)
DK (1) DK2276760T3 (fr)
DO (1) DOP2010000301A (fr)
EA (1) EA019640B1 (fr)
EC (1) ECSP10010602A (fr)
ES (1) ES2476265T3 (fr)
GE (1) GEP20135846B (fr)
HR (1) HRP20140588T1 (fr)
IL (1) IL208463A (fr)
MA (1) MA32283B1 (fr)
ME (1) ME01887B (fr)
MX (1) MX2010011138A (fr)
MY (1) MY152475A (fr)
NZ (1) NZ588562A (fr)
PE (1) PE20100734A1 (fr)
PL (1) PL2276760T3 (fr)
PT (1) PT2276760E (fr)
RS (1) RS53378B (fr)
SI (1) SI2276760T1 (fr)
UA (1) UA104422C2 (fr)
UY (1) UY32131A (fr)
WO (1) WO2009125873A1 (fr)
ZA (1) ZA201007682B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2014085486A2 (fr) 2012-11-30 2014-06-05 Waters Technologies Corporation Procédés et appareil pour l'analyse de métabolites de la vitamine d
EP2931734B1 (fr) * 2012-12-17 2020-12-02 Merck Sharp & Dohme Corp. Nouveaux composés activateurs de glucokinase, compositions contenant de tels composés, et méthodes de traitement

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505612A (ja) 1991-03-01 1993-08-19 ハー・ルンドベック・アクティーゼルスカブ 高血圧症及び末梢血管疾患の治療法
US6506901B2 (en) * 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
CN101103977A (zh) 2002-06-05 2008-01-16 株式会社医药分子设计研究所 糖尿病治疗药
EP1532980A1 (fr) 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes
WO2006089397A1 (fr) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Procédés pour traiter l’arthrite à l’aide de composés trihétérocycliques
US8957070B2 (en) * 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
WO2007037534A1 (fr) * 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. Derive indole substitue en position 2 par un groupe heteroaryle
RU2454415C9 (ru) 2006-10-19 2013-02-27 Такеда Фармасьютикал Компани Лимитед Производное индола
DK2178870T3 (en) * 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
KR101133772B1 (ko) * 2007-12-20 2012-04-24 주식회사 엘지생명과학 글루코키나아제 활성화제 및 이를 활성성분으로 함유하는 약제학적 조성물
US20100291533A1 (en) * 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
US8557805B2 (en) * 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof

Also Published As

Publication number Publication date
HRP20140588T1 (hr) 2014-08-01
ECSP10010602A (es) 2011-03-31
CN102056924B (zh) 2014-05-21
CA2720686A1 (fr) 2009-10-15
AR073609A1 (es) 2010-11-17
SI2276760T1 (sl) 2014-05-30
CR11730A (es) 2010-12-08
UA104422C2 (uk) 2014-02-10
WO2009125873A1 (fr) 2009-10-15
CN102056924A (zh) 2011-05-11
RS53378B (sr) 2014-10-31
EA019640B1 (ru) 2014-05-30
HK1152932A1 (en) 2012-03-16
IL208463A0 (en) 2010-12-30
BRPI0910912A2 (pt) 2015-08-11
IL208463A (en) 2015-07-30
DK2276760T3 (da) 2014-05-26
PT2276760E (pt) 2014-05-28
UY32131A (es) 2010-11-30
EP2276760A1 (fr) 2011-01-26
MY152475A (en) 2014-10-15
PL2276760T3 (pl) 2014-09-30
GEP20135846B (en) 2013-06-10
ZA201007682B (en) 2011-12-28
EA201071180A1 (ru) 2011-04-29
CY1115247T1 (el) 2017-01-04
AU2009234666A1 (en) 2009-10-15
US8673942B2 (en) 2014-03-18
ES2476265T3 (es) 2014-07-14
KR20110002472A (ko) 2011-01-07
AU2009234666B2 (en) 2014-02-20
DOP2010000301A (es) 2010-12-31
CO6321240A2 (es) 2011-09-20
NZ588562A (en) 2012-07-27
JP5528348B2 (ja) 2014-06-25
US20110098297A1 (en) 2011-04-28
EP2276760B1 (fr) 2014-04-09
MX2010011138A (es) 2010-11-12
ME01887B (me) 2014-12-20
PE20100734A1 (es) 2010-11-18
JP2011516403A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
MA32283B1 (fr) Composes cycliques condenses et utilisation de ceux-ci
MA30890B1 (fr) Compose indole
MA34713B1 (fr) Compose bicyclique
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA65131B1 (fr) Utilisation d'un inhibiteur d'ezh2 dans la préparation d'un médicament pour le traitement d'un lymphome à cellules t
MA32171B1 (fr) Compose heterocyclique
MA32965B1 (fr) Derives de sulfonamides
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
MA39246A1 (fr) Composé hétérocyclique fusionné
MA39247B1 (fr) 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
MA35611B1 (fr) Composé inhibiteur de la signalisation par la voie notch
MA31419B1 (fr) Derives de pyridine
MA34245B1 (fr) Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA29926B1 (fr) Derives de pyrazine
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
WO2018194181A8 (fr) Composés hétérocycliques utiles en tant que modulateurs des récepteurs de l'acétylcholine
MA62175B1 (fr) Promédicament de dérivés de pyrrolidone en tant qu'activateur de glucokinase
ATE553077T1 (de) Peptidaseinhibitoren